Objective To investigate the effects of Qili-Qiangxin capsule on cardiac and pulmonary functions in heart failure patients with chronic pulmonary heart disease. Methods A total of 64 heart failure patients with chronic pulmonary heart disease were divided into two groups with the method of random sampling: a treatment group (33 patients) and a control group (31 patients). The patients in the control group received conventional treatment, those in the control group received Qili-Qiangxin capsule on this basis the treatment group for 7 days. The changes of the cardiac and pulmonary functions, and plasma N-terminal pro B-type natriuretic peptide (NT-proBNP) were compared between two groups. Results The total effective rate in the treatment group was significantly higher than that of the control group (90.90% vs. 77.42%; χ2=3.908, P<0.05). There were significant difference between two groups in left ventricular ejection fraction (50.73% ± 7.23%vs. 45.22%± 6.36%;t=3.229, P=0.002), stroke volume (63.64 ± 8.38 ml vs. 56.73 ± 8.15 ml;t=3.341, P=0.001), right ventricular end-diastolic diameter (48.39 ±5.56 mm vs. 52.61 ± 6.95 mm; t=2.690, P=0.009), mean pulmonary arterial pressure (21.73 ± 5.78 mmHg vs. 27.26 ± 6.16 mmHg; t=3.705, P=0.001), plasma NT-proBNP level (535.73 ± 175.78 pg/ml vs. 831.26 ± 228.26 pg/ml; t=5.824, P=0.000), forced expiratory volume in first second (60.32% ± 5.56% vs. 48.61% ± 4.67%; t=9.093, P=0.000), percentage of forced expiratory volume in first second to forced vital capacity (66.73%± 5.78%vs. 58.26%± 5.34%;t=6.078, P=0.000), arterial oxygen saturation (96.73%± 5.78%vs. 93.26%± 5.26%;t=2.507, P=0.015), arterial partial pressure of oxygen (82.73 ± 16.78 mmHg vs. 67.26 ± 13.26 mmHg;t=4.075, P=0.000) arterial partial pressure of carbon dioxide (46.73 ± 8.78 mmHg vs. 54.26 ± 9.26 mmHg; t=3.339, P=0.00). Conclusion Qili-Qiangxin capsule can improve cardiac and pulmonary functions in heart failure patients with chronic pulmonary heart disease.